VTRS - Viatris Inc. (VTRS) R&D Event (Transcript)
2024-03-27 15:26:02 ET
Viatris Inc. (VTRS)
R&D Event
March 27, 2024 10:00 AM ET
Company Participants
Bill Szablewski - Head of Capital Markets
Scott A. Smith - Chief Executive Officer
Rajiv Malik - President
Philippe Martin - Chief R&D Officer
Deepak L. Bhatt - Director of Mount Sinai Fuster Heart Hospital
Anca Askanase - Founder and Clinical Director of Columbia University No Lupus Center
Doretta Mistras - Chief Financial Officer
Conference Call Participants
Jason Gerberry - Bank of America
Glen Santangelo - Jefferies
Nathan Rich - Goldman Sachs
Ekaterina Knyazkova - JPMorgan
Afsah Quadri - Barclays
Presentation
Bill Szablewski
Good morning everyone and welcome. I'm Bill Szablewski, Head of Capital Markets for Viatris. It's a pleasure to have you all here today for our Viatris R&D event.
Before we begin, there will be a brief forward-looking statement. During today's discussion, we may make forward-looking statements on a number of matters, including our pipeline and strategic initiatives. These statements are subject to risks and uncertainties. Please refer to today's slides and our SEC filings for more information.
And with that, turning to today's agenda. With us today from Viatris is our CEO, Scott Smith, who will be providing a strategic overview. Following Scott will be our President, Rajiv Malik, who will be talking about our durable and high margin organic pipeline. Following Rajiv will be Philippe Martin, our Chief R&D Officer, who is going to be discussing the Idorsia collaboration, our two Phase 3 assets of Selatogrel and Cenerimod. And with Philippe today are two distinguished key opinion leaders. Following Philippe will be our CFO, Doretta Mistras, who will be talking about the structuring of the Idorsia collaboration, the commercial overview, and the opportunities that we see with these assets. And lastly, following today's presentation, we will have a question-and-answer session, so we please ask that you hold your questions to the end.
And with that, I'd like to hand it over to our CEO, Scott Smith.
Scott A. Smith
Thank you, Bill. So, good morning, everybody, and welcome to our event. I'm very excited about where we are as a company and about our new partnership with Idorsia and the potential it has to broaden our reach and our pipeline.
Before we get into the bulk of the presentation, I just want to let everybody know how personally excited I am about the two assets we're going to talk about, the two new assets Selatogrel and Cenerimod. I believe they both have the potential to not only be blockbuster assets, but to be significant advances in terms of unmet medical need in acute MI and in SLE. As you will see today, I believe Viatris is well positioned not only to complete, but to accelerate the development and commercialization of these two important assets.
So for those of you who are new to the story, here's just a little snapshot of Viatris. We are an extraordinarily strong and diverse company. We have -- we operate in 165 countries, about over 30,000 employees worldwide. In 2023, we did over $15 billion in revenue, over $5 billion in adjusted EBITDA, and approximately $2.4 billion in free cash flow....
Viatris Inc. (VTRS) R&D Event (Transcript)